Capricor Therapeutics (CAPR) Current Deferred Revenue (2014 - 2026)

Capricor Therapeutics' Current Deferred Revenue history runs 9 years deep, the most recent figure standing at $12.0 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue changed 0.0% year-over-year to $12.0 million; the TTM figure through Mar 2026 stood at $12.0 million (changed 0.0% YoY), while the FY2025 annual figure was $12.0 million, changed 0.0% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $12.0 million, roughly flat from $12.0 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $40.0 million in Q1 2022, with the low at $12.0 million in Q4 2024.
• The 5-year median for Current Deferred Revenue is $15.7 million (2022), against an average of $19.0 million.
• The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue jumped 86.16% in 2023, then sank 50.56% in 2024.
• Capricor Therapeutics' Current Deferred Revenue stood at $18.0 million in 2022, then soared by 34.98% to $24.3 million in 2023, then sank by 50.56% to $12.0 million in 2024, then changed by 0.0% to $12.0 million in 2025, then changed by 0.0% to $12.0 million in 2026.
• Business Quant data shows CAPR's Current Deferred Revenue at $12.0 million in Q1 2026, $12.0 million in Q4 2025, and $12.0 million in Q3 2025.